Amgen's latest immuno-oncology drug comes through in Phase II

Amgen's ($AMGN) new immuno-oncology treatment demonstrated promising efficacy in a midstage trial on a rare blood cancer. In Phase II, the antibody, marketed as Bincyto, spurred complete remission or complete remission with partial hematological recovery in "a clinically meaningful number of patients" with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), the company said, keeping details to itself until a later medical meeting. Blincyto, formerly blinatumomab, won a speedy approval this year to treat Philadelphia chromosome-negative ALL, and Amgen is working to expand the therapy's adoption. Release